You are here: Home » News-CM » Companies » News
Business Standard

Shilpa Medicare launches an anticancer drug 'DASASHIL'

Health Medical Pharma

Capital Market 

Shilpa Medicare announced the launch of Indian branded generic of Dasatinib, an anticancer drug with a brand name DASASHIL.

DASASHIL is First Branded Generic Anticancer Drug with all dosage strength 20/ 50/ 70/ 100 mg tablets which is used for the treatment of Chronic Myeloid Leukaemia (CML)

The Drug Substance patent on Dasatinib was owned by Bristol-Myers-Squibb and had expired on 12 April 2020.

Current, monthly therapy cost of innovator is approximately 1.65 Lacs, with the launch of DASASHIL monthly cost of treatment will be reduced drastically to Rs. 6440/- as monthly therapy cost.

The products are being manufactured and supplied from the state-of-the-art US-FDA approved manufacturing facility.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, April 24 2020. 09:17 IST